Literature DB >> 327919

Amoxicillin therapy of acute urinary infections in adults.

A R Ronald, F A Jagdis, G K Harding, S A Hoban, P L Miur, M J Gurwith.   

Abstract

Fifty-two patients, 48 females and 4 males, with suspected urinary infection were treated with amoxicillin. Twenty-two females with presumed bladder infection were treated with amoxicillin, 250 mg three times a day for 7 days; 26 females and 4 males with presumed renal infection were treated with amoxicillin, 500 mg three times a day for 14 days. Five patients were immediate treatment failures, with positive urine cultures during therapy. All five patients had been infected with amoxicillin-resistant urinary pathogens. Three patients, treated as for bladder infections, reinfected during 6 weeks of follow-up, and only one relapsed. Two patients, treated as for renal infections, reinfected, whereas four relapsed. During therapy, amoxicillin-susceptible gram-negative rods were eradicated from the periurethral area in all but one patient. Of 28 patients studied, 19 acquired a predominant growth of either resistant aerobic gram-negative rods or Candida albicans from periurethral cultures. Our findings suggest that these two regimens of amoxicillin achieve satisfactory cure rates in urinary infection, but both regimens significantly alter the normal periurethral flora.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 327919      PMCID: PMC352074          DOI: 10.1128/AAC.11.5.780

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Bacteriuria localization and response to single-dose therapy in women.

Authors:  A R Ronald; P Boutros; H Mourtada
Journal:  JAMA       Date:  1976-04-26       Impact factor: 56.272

2.  Pharmacologic studies of amoxicillin in nonfasting adults.

Authors:  T G Vitti; M J Gurwith; A R Ronald
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

3.  Comparison of amoxicillin and ampicillin in the treatment of urinary tract infections.

Authors:  D Gilbert
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

4.  Amoxicillin in the treatment of urinary tract infections.

Authors:  M Turck; H H Handsfield; K K Holmes
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

5.  Use of amoxicillin in the treatment of urinary tract infections.

Authors:  G B Miller; R J Duma; F G Middleton; D M Poretz
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

6.  Treatment trials in urinary tract infection (UTI) with special reference to the effect of antimicrobials on the fecal and periurethral flora.

Authors:  J Winberg; T Bergström; K Lincoln; G Lidin-Janson
Journal:  Clin Nephrol       Date:  1973 May-Jun       Impact factor: 0.975

7.  Antibody-coated bacteria in the urine and the site of urinary-tract infection.

Authors:  V Thomas; A Shelokov; M Forland
Journal:  N Engl J Med       Date:  1974-03-14       Impact factor: 91.245

8.  Urinary infection localization.

Authors:  P Boutros; H Mourtada; A R Ronald
Journal:  Am J Obstet Gynecol       Date:  1972-02-01       Impact factor: 8.661

  8 in total
  4 in total

1.  Changes in periurethral microflora after antimicrobial drugs.

Authors:  K J Lidefelt; I Bollgren; C E Nord
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

2.  Trimethoprim-rifampin, a new combination agent: efficacy in localized urinary infection and influence on microflora.

Authors:  A M Bourgault; K R Forward; A R Ronald; G K Harding; M Thomson; G Grey
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

3.  Prospective comparison of amoxicillin-clavulanic acid and cefaclor in treatment of uncomplicated urinary tract infections.

Authors:  M J Gurwith; G E Stein; D Gurwith
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282.

Authors:  John O'Donnell; Angela Tanudra; April Chen; Daniel Hines; Ruben Tommasi; John Mueller
Journal:  ACS Infect Dis       Date:  2020-05-14       Impact factor: 5.084

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.